Logo

DiagnoCure

DiagnoCure Board Votes to Liquidate, Dissolve Company

The plan, which is subject to shareholder approval, comes after the company failed to find buyers for its prostate and colorectal cancer tests.

DiagnoCure's Q4 Revenues Fall as Net Loss Widens

The life sciences company said the loss is mostly attributable to a decrease in royalty revenue from its PCA3 prostate cancer biomarker assets.

DiagnoCure Sells PCA3 Prostate Cancer Assets to Hologic's Gen-Probe for C$6.5 Million

Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.

DiagnoCure Q1 Revenues Dip 3 Percent

The firm also said that it is looking for marketing partners for its multimarker urine-based prostate cancer test, which was validated in 500 patients.

In Brief This Week: Agilent Technologies; Diagnocure; KineMed, Pfizer; PositiveID; SomaLogic

NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income.

Jun 5, 2014

DiagnoCure Licenses Multi-Marker CRC Staging Test to China's Shuwen Biotech
Premium

Mar 20, 2014

DiagnoCure Prods Commercial Partner Hologic to Step Up Marketing for PCA3 Test or Give it Back
Premium

Mar 17, 2014

DiagnoCure Q1 Revenues Fall 12 Percent on Weak Sales of Hologic-marketed Prostate Cancer Assay

Jun 3, 2013

DiagnoCure's Q2 Revenues Fall 85 Percent

Mar 11, 2013

DiagnoCure Q1 Revenues Slide 70 Percent

Jan 14, 2013

DiagnoCure Q4 Revenues Slide 59 Percent, Terminates Deal with Signal Genetics

Sep 6, 2012

DiagnoCure Posts Sharp Q3 Revenue Increase; Warns It May Not Receive Payment for Services Rendered

Jun 6, 2012

Payment from Gen-Probe Drives Sharp Q2 Revenue Increase for DiagnoCure

Mar 30, 2012

DiagnoCure's Q1 Revenues Jump 90 Percent

Sep 9, 2011

DiagnoCure's Q3 Revenues Shrink 12 Percent

Aug 17, 2011

Canada Approves Gen-Probe's Prostate Cancer Assay

Jul 5, 2011

Signal Genetics Gains CLIA Lab, Broadens Test Menu in $13.3M DiagnoCure Deal
Premium

Jun 29, 2011

Signal Genetics Inks $13.3M Deal to Commercialize DiagnoCure's Colorectal Cancer Test, Buy CLIA Lab

Aug 25, 2010

DiagnoCure Retains JMP to Help with Lab Business

Aug 3, 2010

DiagnoCure Laboratory Gets New York Permit

Oct 5, 2009

DiagnoCure, Lab21 Ink UK Sales Pact

Jun 9, 2009

DiagnoCure Cuts Q2 Loss as Revenues Drop

May 1, 2009

Gen-Probe, Diagnocure Amend Prostate Cancer Test Deal

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.